|
An ELISA for the determination of human NGAL in urine, plasma or serum. NGAL is a new early biomarker for diagnosing acute kidney injury (AKI). NGAL is a potential new biomarker for the acute kidney injury (AKI). Under normal conditions, NGAL levels are low in urine and plasma, but they rise sharply from basal levels in response to kidney injury and peaks within a very short time – as much as 24 hours or more before any significant rise in serum creatinine. The finding of a raised urinary or plasma level of NGAL cannot be independently diagnostic of any single pathology, since a variety of independent pathologies (e.g. inflammation, infection and certain types of cancer) are associated with raised levels of urinary or plasma NGAL. Kit features
 |